Merck Invests €70 million to Expand ADC Manufacturing for Novel Cancer Therapies
Triples manufacturing capacity to meet increased global demand for antibody-drug conjugates (ADCs)
Advertisement
Merck announced a € 70 million expansion of its ADC manufacturing capabilities and capacity at its bioconjugation Center of Excellence facility in St. Louis, Missouri, USA. This investment will triple existing capacity and enhance the company’s contract development and manufacturing organization (CDMO) offering, reinforcing its commitment to clients and patients.

The investment represents a critical step in the company’s ongoing growth journey to partner with new and existing clients as they advance their drug development pipelines. With additional capacity and by scaling utilities and enhancing Process and Analytical Development (PAD) labs, Merck will provide industry-leading support for early-stage and commercial bioconjugates. The company’s goal is to ensure clients can bring their innovations to market more effectively and with shorter turnaround times.
“We are shaping tomorrow’s cancer care, today. With this investment, we are not just enhancing our capabilities; we are investing in our clients’ success by accelerating innovation and development to ultimately deliver novel therapies to patients more quickly,” said Benjamin Hein, Head of Life Science Services, Life Science business of Merck. “ADCs represent a transformative approach to oncology, enabling targeted therapies that minimize damage to healthy tissues. As the market for this novel modality grows and the medical community adopts them as first-line treatments, it may mean that fewer patients need invasive treatments like chemotherapy and radiation that cause significant side effects.”
Most read news
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Lonza expands bioconjugation in Visp with two additional manufacturing suites

Daiichi Sankyo's investments in cancer drugs are taking shape - From Bavaria to the world: Daiichi Sankyo transfers technology for the development and production of antibody-drug conjugates to Germany

Waldner: Ground-breaking for new powder coating plant

Roche lays the foundation for the diagnostics production of the future in Germany - Investment of more than 600 million euros in a high-tech production center - Roche's largest single investment in Germany to date

ProBioGen expands protein and virus manufacturing to drive continued growth

Enduro Genetics raises €12 million to unlock the future of scalable bioproduction - Patented cell reprogramming technology "addicts" cells to high production and integrates seamlessly into any microbial bioproduction host

Sensirion opens additional production building in Debrecen

Frank Winkler receives the Brain Prize 2025 - The interaction between the nervous system and cancer is increasingly coming into focus

CorTec Welcomes Dr. Frank Desiere as Chief Executive Officer - A Strengthened Leadership Team to Accelerate Growth and Innovation

New Leadership at Andreas Hettich GmbH - After 20 years of successful leadership by the Eberle family, the Hettich Group is entering a new, forward-looking phase

Managing Director Peter Sölkner leaves Vetter - Managing Director Carsten Press takes over the relevant departments
